Salumets · Aging cell 2022 · Cross-sectional observational and biomarker development study · n=?

Epigenetic quantification of immunosenescent CD8 + TEMRA cells in human blood.

Cited 68 times in the scientific literature.

Level 4 - case-series / case-control

Cross-sectional observational and biomarker development study

PubMed 35397197 · doi:10.1111/acel.13607 · record verified 2026-08-29

What was done

Researchers conducted detailed T-cell profiling in individuals over 65 years of age to evaluate interindividual variation in CD8+ effector memory CD45RA+ (TEMRA) populations. They analyzed associations between CD8+ TEMRA cell frequencies, chronological age, cytomegalovirus (CMV) antibody titers, and a panel of over 90 circulating inflammation proteins. They then performed deep-amplicon bisulfite sequencing against flow cytometry benchmarks to build a computational model predicting CD8+ TEMRA cell proportions directly from whole blood genomic DNA methylation.

What was found

The abstract reports no exact numeric effect sizes, sample size, or p-values. It found substantial interindividual variation in CD8+ TEMRA frequencies among adults over 65. Proportions correlated positively with CMV antibody levels but did not correlate with chronological age. Among the inflammation proteins measured, plasma TRANCE/RANKL levels associated with several differentiated T-cell subsets, including CD8+ TEMRA and CD28- subsets. A computational DNA methylation model was successfully developed to predict these cell proportions.

Why it matters

Immunosenescent CD8+ TEMRA cells are linked to chronic inflammatory states and immune decline, largely driven by CMV status rather than calendar age alone. An epigenetic assay allows high-throughput estimation of these cells from stored whole blood DNA without requiring fresh cell isolation or flow cytometry.

Limits

The abstract does not provide the sample size (n), exact correlation values, or validation metrics for the computational prediction model. The study was cross-sectional, restricted to adults over 65 years of age, and cannot establish causal relationships between TRANCE/RANKL, CMV exposure, and T-cell differentiation.

Cited by